About us

At OncoArendi we search for innovative ways to help patients with incurable diseases.

We are a biotech company discovering and developing new drugs up to clinical proof-of-concept`. We focus on small molecules and pursue innovative drug target platforms that have broad therapeutic potential. Our ambition is to discover, develop and commercialize breakthrough medicines in cancer, fibrotic and inflammatory diseases. We constantly seek partnerships with academic, clinical and business partners.

We play a leading role in shaping the Polish biotech industry by pioneering innovative drug discovery and providing career opportunities for top local and international talent. We are working together to bring first-in-class drugs discovered in Poland to the global market.

Read more

Our Values

Integrity and reliability are inscribed into our approach and way of dealing with colleagues, associates and business partners.
We treat others the way we would like to be treated. We value diversity, we support each other, we promote dialogue and discussion based on openness and mutual respect.
Our enthusiasm and commitment to what we do translates into the success of our team and of the entire company. We are always willing to face new challenges.
Creativity and innovation constitute the foundation of our activity. We discover new therapies, based on the knowledge and experience of our entire team.
Responsibility & Accountability
We ensure top quality in all our work and the tasks performed. We are accountable for achieving our common goals.

The Team

A seasoned management team with several decades of relevant experience in drug discovery and development from large pharma, small biotech, technology-based startups, CROs and academic environments.

Read more


An attractive portfolio of projects focusing on novel biological targets with high potential market value ("first in class" drug candidates) for the treatment of inflammatory and fibrotic diseases as well as cancer.

Read more


OncoArendi has an established global network of academic collaborators and professional CROs. The company is seeking for new alliances and partnerships early in the drug development process to leverage its core competencies.

Read more

Investment History

OncoArendi Therapeutics was founded in 2012. Following the Founders seed and in-kind contributions, OncoArendi raised a seed and two series A rounds of financing followed by a successful IPO on the Warsaw Stock Exchange (WSE) in April of 2018, raising a total of 91 million PLN approx. 24 million USD, based on averaged variable exchange rate over the last 7 years.

In addition OncoArendi has been able to significantly leverage the private capital raised with non-dilutive grants, with total funding of about 183 million. This funding was received from Polish and international funding agencies including the National Center for Research and Development (NCBR, Poland), The National Institutes of Health (NIH, USA), The European Commission and the Polish Agency of Enterprise Development (PARP).

This funding has allowed OncoArendi Therapeutics to progress the first of its programs (OATD-01) to Phase II of its other three ongoing programs up to pre-IND stage, lead optimization and early discovery, respectively.

Read more
Magda KućmaHome